


Supplementary file



Supplementary Fig. S1. Proportion of patients achieving a meaningful improvement for work productivity loss (A) and activity impairment (B) at Week 24 in integrated SPIRIT-P1/SPIRIT-P2 analysis set by baseline CPDAI severity. CPDAI severity was defined as peripheral arthritis domain score ≥ 3 and total score ≥ 8 .

* $p < 0.001$, # $p < 0.05$ versus placebo based on Fisher's test. CPDAI: Composite Psoriatic Disease Activity Index; IXEQ2W: ixekizumab 80 mg every 2 weeks; IXEQ4W: ixekizumab 80 mg once every 4 weeks; MCID: minimal clinically important difference; Ns: number of patients in each subgroup; NRI: non-responder imputation.